Cartesian Therapeutics (RNAC) Receivables - Net (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Receivables - Net for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.
- Quarterly Receivables - Net rose 27.87% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 27.87% year-over-year, with the annual reading at $1.1 million for FY2025, 27.87% up from the prior year.
- Receivables - Net for Q4 2025 was $1.1 million at Cartesian Therapeutics, up from $722000.0 in the prior quarter.
- The five-year high for Receivables - Net was $32.0 million in Q2 2024, with the low at $354000.0 in Q2 2025.
- Average Receivables - Net over 5 years is $7.3 million, with a median of $6.2 million recorded in 2022.
- The sharpest move saw Receivables - Net surged 494.97% in 2024, then crashed 98.9% in 2025.
- Over 5 years, Receivables - Net stood at $9.9 million in 2021, then plummeted by 33.47% to $6.6 million in 2022, then dropped by 11.01% to $5.9 million in 2023, then plummeted by 85.14% to $872000.0 in 2024, then rose by 27.87% to $1.1 million in 2025.
- According to Business Quant data, Receivables - Net over the past three periods came in at $1.1 million, $722000.0, and $354000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.